|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61K 31/716 | |||
| A61P 35/00 | |||
| A61K 45/00 |
| (11) | Number of the document | 2461870 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10802912.5 |
| Date of filing the European patent application | 2010-07-22 | |
| (97) | Date of publication of the European application | 2012-06-13 |
| (45) | Date of publication and mention of the grant of the patent | 2017-09-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/042925 |
| Date | 2010-07-22 |
| (87) | Number | WO 2011/011617 |
| Date | 2011-01-27 |
| (30) | Number | Date | Country code |
| 271514 P | 2009-07-22 | US |
| (72) |
VASILAKOS, John, P., US
|
| (73) |
Biothera, Inc.,
3388 Mike Collins Drive, Eagan, MN 55121,
US
|
| (54) | COMPOSITION COMPRISING BETA-GLUCAN AND AN EGF-R ANTIBODY OR AN EGF-R ANTAGONIST FOR USE IN THE TREATMENT OF KRAS-MUTATED TUMORS |
| COMPOSITION COMPRISING BETA-GLUCAN AND AN EGF-R ANTIBODY OR AN EGF-R ANTAGONIST FOR USE IN THE TREATMENT OF KRAS-MUTATED TUMORS |